Association between comorbidity and clinical characteristics of MS

Acta Neurologica Scandinavica

Volumn 124, Issue 2, 2011, Pages 135-141

  Marrie, R A ^a   Horwitz, R I ^b   Cutter, G ^c   Tyry, T ^d   Vollmer, T ^e  

^a UNIVERSITY OF MANITOBA   (Canada)

^b Stanford California and Cofounder   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d BARROW NEUROLOGICAL INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO   (United States)

Author keywords

Comorbidity; Epidemiology; Multiple sclerosis; Smoking

Indexed keywords

ADULT; ARTICLE; AUTOIMMUNE DISEASE; BODY HEIGHT; BODY WEIGHT; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE SCLEROSIS; OBESITY; RECURRENT DISEASE; SMOKING; SYMPTOM; VASCULAR DISEASE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; COMORBIDITY; DIABETES MELLITUS; FEMALE; HEART DISEASES; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MULTIPLE SCLEROSIS; PROGNOSIS; QUESTIONNAIRES; REGISTRIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 79960147043     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01436.x     Document Type: Article

References (35)

1. De Reuck J, De Weweire M, Van Maele G, Santens P. Comparison of age of onset and development of motor complications between smokers and non-smokers in Parkinson's disease. J Neurol Sci 2005;231:35-9.
2. Healy BC, Ali EN, Guttmann CRG et al. Smoking and disease progression in multiple sclerosis. Arch Neurol 2009;66:858-64.
3. Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status, and multiple sclerosis. Multiple Sclerosis 2008;14:1091-8.
4. Karni A, Abramsky O. Association of MS with thyroid disorders. Neurology 1999;53:883-5.
5. Schmidt S, Wessels L, Augustin A, Klockgether T. Patients with multiple sclerosis and concomitant uveitis/periphlebitis retinae are not distinct from those without intraocular inflammation. J Neurol Sci 2001;187:49-53.
6. Tourbah A, Clapin A, Gout O et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol 1998;55:517-21.
7. Consortium of Multiple Sclerosis Centers. NARCOMS Multiple Sclerosis Registry, 2008.
8. Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T. Validation of the NARCOMS Registry: diagnosis. Multiple Sclerosis 2007;13:770-5.
9. Katz JN, Chang LC, Sangha O, Fossel AH, Bates DW. Can comorbidity be measured by questionnaire rather than medical record review? Med Care 1996;34:73-84.
10. Okura Y, Urban LH, Mahoney DW, Jacobsen SJ, Rodeheffer RJ. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57:1096-103.
11. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156-63.
12. Bergmann MM, Jacobs EJ, Hoffmann K, Boeing H. Agreement of self-reported medical history: comparison of an in-person interview with a self-administered questionnaire. Eur J Epidemiol 2004;19:411-6.
13. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn's Disease and Ulcerative Colitis in a central Canadian Province: a population-based study. Am J Epidemiol 1999;149:916-24.
14. Marrie RA, Cutter G, Tyry T, Hadjimichael O, Campagnolo D, Vollmer T. Changes in the ascertainment of multiple sclerosis. Neurology 2005;65:1066-70.
15. Marrie RA, Cutter G, Tyry T, Vollmer T, Campagnolo D. Does multiple sclerosis-associated disability differ between races? Neurology 2006;66:1235-40.
16. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: John Wiley & Sons, 1989.
17. Spadaro M, Amendolea MA, Mazzucconi MG et al. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. Multiple Sclerosis 1999;5:121-5.
18. Koch-Henriksen N, Sorensen PS. The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurology 2010;9:520-32.
19. Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology 2009;73:1543-50.
20. Li J, Johansen C, Bronnum-Hansen H, Stenager E, Koch-Henriksen N, Olsen J. The risk of multiple sclerosis in bereaved parents. A nationwide cohort study in Denmark. Neurology 2004;62:726-9.
21. Irwin MR, Miller AH. Depressive disorders and immunity: 20years of progress and discovery. Brain Behav Immunol 2007;21:374-83.
22. Duquette P, Girard M. Hormonal factors in susceptibility to multiple sclerosis. Curr Opin Neurol Neurosurg. 1993;6:195-201.
23. Marrie RA, Horwitz RI, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology 2009;72:117-24.
24. Marrie RA, Rudick R, Horwitz R et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010;74:1041-7.
25. Dallmeijer AJ, Beckerman H, De Groot V, Van De Port IGL, Lankhorst GJ, Dekker J. Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis. J Rehab Med 2009;41:322-6.
26. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-94.
27. Rudick RA, Stuart WH, Calabresi PA et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
28. Hansen B, Vogel PA, Stiles TC, Gotestam KG. Influence of co-morbid generalized anxiety disorder, panic disorder and personality disorders on the outcome of cognitive behavioural treatment of obsessive-compulsive disorder. Cogn Behav Ther 2007;36:145-55.
29. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.
30. Mandell LA, Wunderink RG, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults. Clin Infect Dis 2007;44:S27-72.
31. Kattan MW, Cowen ME, Miles BJ. A decision analysis for treatment of clinically localized prostate cancer. J Gen Intern Med 1997;12:229-305.
32. Asch DA, Jedrziewski MK, Christakis NA. Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997;50:1129-36.
33. Collins JG. Prevalence of selected chronic conditions, United States, 1986-88. National Center for Health Statistics. Vital Health Stat 1993;10:1-87.
34. Horton M, Rudick RA, Hara-Cleaver C, Marrie RA. Validation of a Self-Report Comorbidity Questionnaire for Multiple Sclerosis. Neuroepidemiology 2010;35:83-90.
35. Marrie RA. The influence of comorbid diseases and health behaviors on clinical characteristics, disability at diagnosis, and disability progression in multiple sclerosis. Epidemiology & Biostatistics Cleveland: Case Western Reserve University, 2007.